Seaport Research analyst Jay Goldberg argued that Nvidia is one of the leading beneficiaries of the current AI spending boom, but its prospects are "well understood and largely priced into the stock."
Edgewater noted that the mobile gaming macro environment appears to be decelerating gradually, while competition from both Meta and Alphabet is intensifying.
According to the terms of the deal, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million.
However, the e-commerce player reported a net loss of $52.1 million during the quarter compared to a profit of $63 million in the same quarter a year ago, reflecting an impairment charge of $101.7 million to the goodwill of Reverb.
Humana’s insurance segment benefit ratio came in at 87.4% in the quarter, in line with its estimate of approximately 87.5%, reflecting medical cost trends that aligned with its expectations.
Taylor Wiederhorn will be the new joint leader, replacing Rob Rosen, who will move to a consulting position focused on debt and capital markets for the company.
The Finchat-compiled consensus estimates model earnings per share (EPS) of $5.21 and revenue of $41.36 billion for the first quarter of the fiscal year 2025.
CEO Evan Spiegel noted progress with direct-response advertising solutions, continued momentum in driving performance for small and medium sized businesses and growth of Snapchat+ subscription business.
Amazon finds itself in a catch-22 position, where it has to either absorb higher costs from tariffs, which will hurt margins, or hike prices on its platform and risk losing market share.
Gross margin for the quarter fell 220 basis points sequentially due to higher inventory reserves resulting from older generation products and higher costs to enable time-to-market for new products.
ZEVASKYN is expected to be available beginning in the third quarter of 2025 through ZEVASKYN Qualified Treatment Centers, located across the U.S. with experience in cell and gene therapy.
Amazon clarified that although it considered displaying import charges on items sold through its site for ultra-discount items, the plan “was never approved and not going to happen.”
